Lisa B. Nachtigall, MD
Co-director Neuroendocrine Clinical Center
- Department of Medicine
- Clinical Interests
- Bone disorders related to neuroendocrine dysfunction
- Pituitary disease
- Pituitary tumors
- Reproductive Dysfunction
- Boston: Massachusetts General Hospital
- Medical Education
- MD, New York University School of Medicine
- Residency, New York University School of Medicine
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Endocrinology, Diabetes & Metabolism, American Board of Internal Medicine
- Accepting New Patients
- Insurances Accepted
- Aetna Health Inc.
Blue Cross Blue Shield - Blue Care 65
Blue Cross Blue Shield - Indemnity
Blue Cross Blue Shield - Managed Care
Blue Cross Blue Shield - Partners Plus
Cigna (PAL #'s)
Fallon Community HealthCare
Great-West Healthcare (formally One Health Plan)
Harvard Pilgrim Health Plan - ACD
Harvard Pilgrim Health Plan - PBO
Health Care Value Management (HCVM)
Humana/Choice Care PPO
Medicare - ACD
Neighborhood Health Plan - ACD
Neighborhood Health Plan - PBO
OSW - Maine
OSW - New Hampshire
OSW - Rhode Island
OSW - Vermont
Private Health Care Systems (PHCS)
Tufts Health Plan
United Healthcare (non-HMO) - ACD
United Healthcare (non-HMO) - PBO
Dr. Lisa Nachtigall is the Co- Director of the Neuroendocrine Clinical Center at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. Her primary clinical focus is pituitary disorders and the treatment of patients with acromegaly. She has extensive clinical experience in neuroendocrine disorders and has published clinical research papers in this area. She has received awards for teaching and clinical investigation.
My study of how 100 patients with acromegaly came to diagnosis targeted education on this rare disease to professionals who most likely encounter it. I investigated a long acting somatostatin analog with a novel delivery system. I have contributed to several reviews on acromegaly and hyperprolactinemia and edited chapters on these topics. I have created an acromegaly database, including longitudinal data in over 350 patients, which will improve clinical practice strategies and serve as a resource for clinical investigation and as a model for database construction. I received an investigator initiated award to study long term treatment of acromegaly with somatostatin analogs.
View my most recent publications at PubMed
Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, Hemphill L, Nachtigall L, Loeffler J, Swearingen B, Biller BM, Klibanski A. J Clin Endocrinol Metab. 2010 Feb;95(2):567-77. Epub 2010 Jan 8.
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-na?ve patients with acromegaly.
Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S; SALSA Study Group. Pituitary. 2010 Jun;13(2):115-22.
Neuroendocrine Clinical Center
Zero Emerson Place
Boston, MA 02114-2217
Call the Massachusetts General Hospital physician referral service at 800-711-4644.
Mass General accepts most health insurance plans. Find out what you need to know before coming to Mass General.
Driving to Mass General? Get driving directions or locate a parking lot on the hospital's main campus.